ArticleJHEP reports : innovation in hepatology2024
Dietary pattern modifies the risk of MASLD through metabolomic signature.
Article in JHEP reports : innovation in hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Health and Environmental Impacts, Safety, and Affordability of the EAT-Lancet Planetary Health Diet: A Multidisciplinary Systematic Review and Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns.Molecular nutrition & food research · 2025Trial
- Nutriomic Technologies for Characterizing, Diagnosing, Clustering and Managing Chronic Liver Diseases: Precision Nutrition Implications.International journal of molecular sciences · 2026Review
- Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- From dietary patterns to metabolic phenotypes in MASLD: promise and caution.Hepatology international · 2026Article
- Review
- EAT-Lancet Diet, Plasma Metabolites, and Risk of Peripheral Artery Disease: A Prospective Cohort Study.Journal of the American Heart Association · 2026Article
- The metabolomic signatures mediate associations between physical frailty and metabolic dysfunction-associated steatotic liver disease.Science advances · 2026Article
- PNPLA3-I148M reduces hepatic triacylglycerol secretion and mitigates diet induced left ventricular diastolic dysfunction.Scientific reports · 2026Article
- β-Hydroxybutyrate upregulates hepatic histone β-hydroxybutyrylation modification, promotes the expression of PPARα, and alleviates the hepatic steatosis in MASLD.Clinical epigenetics · 2026Article
- Associations of adherence to the EAT-Lancet and plant-based diets with mortality and life expectancy: two nationwide cohort studies.GeroScience · 2026Article
- Gut microbiota supportive dietary pattern associated with reduced MASLD risk mediated by metabolomic profiles: a prospective cohort study.Nutrition journal · 2026Article
- Association of adherence to the EAT-Lancet diet and risk of uterine cancer: a prospective cohort from the UK Biobank.Frontiers in nutrition · 2026Article
- EAT-Lancet and plant-based diets, plasma metabolomic signatures, and biological aging.npj aging · 2025Article
- Metabolic signature of EAT-Lancet diet in relation to risk of frailty: a prospective cohort study.NPJ science of food · 2025Article
- The Role of a Sustainable Planetary Health Diet in the Prevention of Non-Communicable Diseases and Cause-Specific Mortality: A Narrative Review.Foods (Basel, Switzerland) · 2025Review
- Sex Differences in the Association Between the Korean Healthy Eating Index and Liver Enzymes Among Korean Adults.Nutrients · 2025Article
- Two-Year Mediterranean Diet Intervention Improves Hepatic Health in MASLD Patients.Foods (Basel, Switzerland) · 2025Article
- EAT-Lancet diet and risk of metabolic dysfunction-associated steatotic liver disease and other liver chronic diseases: a large prospective cohort study in the UK Biobank.Frontiers in nutrition · 2025Article
- Osteosarcopenia in metabolic dysfunction-associated steatotic liver disease: from mechanisms to management.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The EAT-Lancet Commission in 2019 advocated a plant-centric diet for health and environmental benefits, but its relation to metabolic dysfunction-associated steatotic liver disease (MASLD) is unclear. We aimed to discover the metabolite profile linked to the EAT-Lancet diet and its association with MASLD risk, considering genetic predisposition. Methods: We analyzed data from 105,752 UK Biobank participants with detailed dietary and metabolomic information. We constructed an EAT-Lancet diet index and derived a corresponding metabolomic signature through elastic net regression. A weighted polygenic risk score for MASLD was computed from associated risk variants. The Cox proportional hazards model was employed to estimate hazard ratios (HRs) and 95% CIs for the risk of MASLD (defined as hospital admission or death). Results: During a median follow-up period of 11.6 years, 1,138 cases of MASLD were documented. Participants in the highest group for the EAT-Lancet diet index had a multivariable HR of 0.79 (95% CI 0.66-0.95) for MASLD compared to the lowest group. The diet's impact was unaffected by genetic predisposition to MASLD ( Conclusions: Higher intake of the EAT-Lancet diet and its associated metabolite signature are both linked to a reduced risk of MASLD, independently of traditional risk factors. Impact and implications: Our analysis leveraging the UK Biobank study showed higher adherence to the EAT-Lancet diet was associated with a reduced risk of metabolic dysfunction-associated steatotic liver disease (MASLD). We identified a unique metabolite signature comprising 81 metabolites associated with the EAT-Lancet diet, potentially underlying the diet's protective mechanism against MASLD. These findings suggest the EAT-Lancet diet may offer substantial protective benefits against MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.